Showing 3081-3090 of 5771 results for "".
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Arcscan's Insight 100 Ophthalmic Ultrasound Imaging System Approved in Chinahttps://modernod.com/news/arcscans-insight-100-ophthalmic-ultrasound-imaging-system-approved-in-china/2482279/ArcScan announced that the ArcScan Insight 100 has received National Medical Products Administration (NMPA) approval in China. The Insight 100 is designed to allow eye surgeons to more accurately determine the appropriate sizing of phakic IOLs for placement behi
- Beyeonics Vision Installs First Beyeonics ONE Digital Exoscopehttps://modernod.com/news/beyeonics-vision-installs-first-beyeonics-one-digital-exoscope/2482278/Beyeonics Vision announced it has installed the first Beyeonics ONE Digital Exoscope at Largo Ambulatory Surgery Center & Eye Institute of West Florida. According to Beyeonics Vision, the Beyeonics ONE Digital Exoscope is designed to enhance precision a
- EyeCRO Presents Phase 2 Results for MiDROPS Platformhttps://modernod.com/news/eyecro-presents-phase-2-results-for-midrops-platform/2482276/EyeCRO has announced that data from the first clinical application of its MiDROPS (Microemulsion Drug Ocular Penetration System) platform technology was presented by Telios Pharma at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA. The presentation
- Humonix Biosciences Appoints Karen Torrejon, PhD, as New CEOhttps://modernod.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/Humonix Biosciences announced the appointment of Karen Torrejon, PhD, as the new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform. Humonix’s platform has bee
- Topcon Healthcare Partners with Microsoft to Deliver AI-Powered ‘Healthcare from the Eye’https://modernod.com/news/topcon-healthcare-partners-with-microsoft-to-deliver-ai-powered-healthcare-from-the-eye/2482274/Topcon Healthcare announced a partnership with Microsoft Corporation to deliver AI-powered ‘Healthcare from the Eye’ solutions to improve healthcare access, cost, and quality. A cloud-based connected network of healthcare providers using the 'Nuance Precision I
- RevOpsis Names Emmett Cunningham, MD, PhD, to Strategic Advisory Boardhttps://modernod.com/news/revopsis-names-emmett-cunningham-md-phd-to-strategic-advisory-board/2482273/RevOpsis Therapeutics announced the appointment of Emmett Cunningham, MD, PhD, to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham brings more than 20 years of experience as a full-time entrepreneur and investor to his new role with RevOpsis. Dr. Cunning
- Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-zenlens-echo-scleral-lenses-in-the-united-states/2482272/Bausch + Lomb announced the US launch of Zenlens Echo, a non-prosthetic, custom scleral contact lens. The Echo is designed to fit a wide variety of corneal shapes and sizes, including patients who have advanced ocular conditions such as corneal degeneration and certain postoperative con
- AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Wet AMDhttps://modernod.com/news/asclepix-therapeutics-completes-enrollment-in-discover-trial-for-wet-amd/2482271/AsclepiX Therapeutics announced the completion of enrollment into the DISCOVER trial (NCT05859776) evaluating the safety and tolerability of three dose strengths of AXT107 (gersizangitide) for wet AMD. In the trial, 15 patients will receive either 125 µg (n=3), 250 &micr
- Alcon to Acquire Israel-Based Belkin Vision, Maker of Eagle SLT Laserhttps://modernod.com/news/alcon-to-acquire-israel-based-belkin-vision-maker-of-eagle-slt-laser/2482270/Alcon has bolstered its glaucoma surgical portfolio after announcing plans to acquire Belkin Vision in deal potentially worth more than $300 million. The deal, which was first reported by Israel-based business news provider, Globes, has been confirmed by Eyewire+. According